Grid is committed to advancing our unique strategy to develop better and safer medicines for our patients. This has and will continue to be our sole mission.

Phase 1b study in patients with refractory, advanced stage (III/IV) and recurrent Non-Small Cell Lung Cancer (NSCLC)

Our Phase 1b study, designed to assess the safety, tolerability and Maximum Tolerated Dose of GT103 as a monotherapy in adult subjects with refractory, advanced stage NSCLC was closed to accrual (at our request) in December 2023. We enrolled in total 31 patients with advanced stage lung cancer.

Phase 2 study in patients with relapsed or refractory metastatic NSCLC

Our Phase 2 GT103 combination trial with Pembrolizumab (Keytruda®) has also been initiated at the sites listed below. Additional clinical trial sites are expected to open soon.

For further support or questions contact:
Grid Therapeutics
Dr. Edward Patz
Duke Thoracic Oncology
Phone number (919) 681-4768